FibroGen Inc. (NASDAQ:FGEN) – Research analysts at William Blair increased their FY2016 earnings per share estimates for FibroGen in a research report issued on Wednesday. William Blair analyst J. Sonnier now expects that the brokerage will post earnings of ($1.17) per share for the year, up from their previous estimate of ($1.40). William Blair also issued estimates for FibroGen’s Q4 2016 earnings at ($0.69) EPS, FY2017 earnings at ($3.07) EPS, FY2018 earnings at ($1.36) EPS and FY2019 earnings at $6.26 EPS.

Other equities research analysts have also recently issued reports about the company. Leerink Swann set a $52.00 price objective on FibroGen and gave the stock a “buy” rating in a research note on Wednesday. Credit Suisse Group AG reissued a “buy” rating and set a $37.00 price objective on shares of FibroGen in a research note on Tuesday, August 9th. Finally, Zacks Investment Research raised FibroGen from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Friday.

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ:FGEN) opened at 22.55 on Friday. FibroGen has a 12-month low of $14.38 and a 12-month high of $31.90. The stock has a 50 day moving average price of $18.74 and a 200-day moving average price of $18.24. The stock’s market capitalization is $1.42 billion.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.21. FibroGen had a negative return on equity of 40.38% and a negative net margin of 45.93%. The firm earned $30.10 million during the quarter, compared to analysts’ expectations of $24.30 million.

In other FibroGen news, CEO Thomas B. Neff sold 37,798 shares of the business’s stock in a transaction that occurred on Tuesday, November 1st. The stock was sold at an average price of $16.76, for a total transaction of $633,494.48. Following the completion of the transaction, the chief executive officer now owns 3,350,871 shares in the company, valued at $56,160,597.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider K Peony Yu sold 2,345 shares of the business’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $18.66, for a total value of $43,757.70. Following the transaction, the insider now owns 206,502 shares of the company’s stock, valued at approximately $3,853,327.32. The disclosure for this sale can be found here. Company insiders own 14.90% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in FGEN. Vanguard Group Inc. raised its position in shares of FibroGen by 8.8% in the second quarter. Vanguard Group Inc. now owns 4,220,201 shares of the biopharmaceutical company’s stock valued at $69,254,000 after buying an additional 339,735 shares during the period. BlackRock Fund Advisors raised its position in shares of FibroGen by 5.7% in the third quarter. BlackRock Fund Advisors now owns 2,170,992 shares of the biopharmaceutical company’s stock valued at $44,940,000 after buying an additional 117,858 shares during the period. BlackRock Institutional Trust Company N.A. raised its position in shares of FibroGen by 12.6% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,449,431 shares of the biopharmaceutical company’s stock valued at $30,003,000 after buying an additional 162,548 shares during the period. State Street Corp raised its position in shares of FibroGen by 15.1% in the first quarter. State Street Corp now owns 1,330,809 shares of the biopharmaceutical company’s stock valued at $28,335,000 after buying an additional 174,369 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of FibroGen by 0.3% in the second quarter. JPMorgan Chase & Co. now owns 1,282,804 shares of the biopharmaceutical company’s stock valued at $21,051,000 after buying an additional 3,482 shares during the period. Institutional investors and hedge funds own 49.76% of the company’s stock.

About FibroGen

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

5 Day Chart for NASDAQ:FGEN

Receive News & Stock Ratings for FibroGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc. and related stocks with our FREE daily email newsletter.